Physician profile
Mary E Belford
NPI 1194719534
$7,345.18
in general payments reported to CMS, 2019-2025
27 companies · $15.05 in 2025
The $15.05 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $213 · 2021: $939 · 2022: $1,675 · 2023: $2,480 · 2024: $1,353 · 2025: $15.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,848.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.48 | 2021-2024 | Vraylar |
| Lundbeck LLC | $741.04 | 2019-2024 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $711.96 | 2019-2024 | Abilify Maintena, Rexulti, Nuedexta |
| Indivior INC. | $576.59 | 2019-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $547.79 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $441.72 | 2019-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $438.92 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $335.65 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Supernus Pharmaceuticals, INC. | $329.59 | 2021-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $321.24 | 2019-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $319.68 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $257.47 | 2019-2022 | |
| Corium, LLC | $245.37 | 2021-2024 | Azstarys |
| Axsome Therapeutics, INC. | $241.39 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $228.65 | 2020-2025 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $192.86 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $114.50 | 2022-2024 | Quviviq |
| Tris Pharma INC | $89.28 | 2023-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $71.83 | 2022-2023 | Fanapt, Hetlioz |
| Acadia Pharmaceuticals INC | $70.89 | 2019-2021 | |
| Allergan, INC. | $58.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $56.39 | 2022-2023 | Belsomra |
| Neos Therapeutics, LP | $50.32 | 2019-2020 | |
| Eisai INC. | $45.43 | 2021 | |
| Shire North American Group INC | $41.96 | 2019 | |
| Biogen, INC. | $36.97 | 2024 | |
| Arbor Pharmaceuticals, INC. | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Belford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.